Merkel Cell Carcinoma Cutaneous Squamous Cell Carcinoma or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined with Pembrolizumab or Cemiplimab (AST-008-102)

Brief description of study

The purpose of the study is to determine the safety, tolerability, and efficacy of cavrotolimod alone and in combination with pembrolizumab (Phase 1b) or cavrotolimod alone and in combination with pembrolizumab or cemiplimab (Phase 2) in patients with advanced solid tumors (Phase 1b) or advanced merkel cell carcinoma (MCC) or cutaneous squamous cell carcinoma (CSCC). We want to recommend a dose of cavrotolimod and a combination regimen for further development. The study drug cavrotolimod is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s20-01784 Identifier: NCT03684785

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.